Paragon Biosciences

Paragon Biosciences Employees

12 people indexed:

Cole Ikkala

VP, Strategic Capital
Darien Parhad

Chief Financial Officer
David Brill

SVP, Portfolio Management
Eric Messner

SVP, Business Development
Greg Aronin

SVP, External Affairs
Jeffrey S. Aronin

Paragon Founder, Chairman and CEO
Kerensa Jimenez

CEO, Paragon Health Capital
Patrick Morris

EVP, Legal Affairs and General Counsel
Sheridan Chaney

1j@kxfd95hlh8f36.53k Sign up to see email

xw@0j2klvhy01yxk.ttt Sign up to see email
Spiro Katerinis

Chief Technology Officer

tx@ze3y9y3v7d0fd.54v Sign up to see email

2w@uxjjeeleu93fv.8x1 Sign up to see email
Stephen Wanaski

SVP, Research & Exploratory Development

zky2q3u@1jf0l6y6fx62z.7dl Sign up to see email

39ldj80@0lfuw77x7044f.wlj Sign up to see email
Timothy Cunniff

EVP, Research & Development

Paragon Biosciences Company Information

Paragon Biosciences is a biopharmaceutical company that specializes in the development of new treatment options for patients with sleep-wake disorders, central nervous system disorders, and other neurological conditions. The company has made significant strides in the pharmaceutical industry by developing and commercializing the first nonscheduled treatment for narcolepsy and is currently in late-stage development of a new class of drug for patients with Tourette syndrome. Leveraging generative AI, Paragon Biosciences designs novel protein systems to develop treatments for diseases that currently have limited options. Additionally, the company is a late-stage cell and gene therapy developer focusing on skin and connective tissue diseases and is pursuing regenerative medicines aimed at restoring vision in patients with degenerative retinal diseases. Recognized for its rapid growth, Paragon Biosciences was ranked among the Top 25 Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500. Recently, the company announced an $81 million financing round to further advance its generative AI capabilities for therapeutic discovery and drug development.

Report inaccurate information